Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study
VB-111 is an experimental gene therapy. Two papers came out at the same time with conflicting results. This phase 1/2 study had very good results but was not as large or well designed as the phase 3 trial. mentioned in the next article. They used the treatment in a few different ways with the best being using the VB-111 alone until progression, then continue VB-111 and add Avastin. My thoughts are that most of the immunotherapy trials fail because they stop the treatment too soon. These treatments take time to work, and sometimes the tumor looks worse before it gets better.
Posted on: 12/25/2019
Click HERE to return to brain tumor news headlines